Nobuaki Ochi

Kawasaki Medical School — Japan

Medicine · Health Sciences

24h-index2.2kcitations304works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(107), Astrophysics and Cosmic Phenomena(64), Lung Cancer Research Studies(39), Dark Matter and Cosmic Phenomena(38), Colorectal Cancer Treatments and Studies(33)

Publications304 total

Co-expression of PD1/PD-L1 on Tumor Cells Is Involved in the Regulation of Cell Proliferation
Anticancer Research·2025
Acute Radiation Esophagitis After Chemoradiotherapy Demonstrating “Tube‐Like” <scp>FDG</scp> Uptake on <scp>PET</scp> ‐ <scp>CT</scp> : Case Report and Literature Review
Cancer Reports·2025· 1 citedOpen Access
Lazertinib: A Cardio‐Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double‐Mutant Tyrosine Kinase Resistant Non‐Small Cell Lung Cancer
Drug Development Research·2025· 1 cited
Influence of Primary Care Physicians on End-of-Life Treatment Choices in Lung Cancer Diagnosed in the Emergency Department
Journal of Personalized Medicine·2025Open Access
Utility of ultrasound-guided transbronchial needle biopsy using an acquire needle in the diagnosis of chest and mediastinal diseases
Japanese Journal of Clinical Oncology·2025
A Case of Duodenal Metastasis From Malignant Pleural Mesothelioma Diagnosed by Gastrointestinal Endoscopy Following Progressive Anemia During Salvage Chemotherapy
Thoracic Cancer·2025Open Access
Efficacy and safety of dose-dense chemotherapy for early-stage breast cancer under prophylactic pegfilgrastim administration: a systematic review and meta-analysis from clinical practice guidelines for the use of G-CSF 2022
International Journal of Clinical Oncology·2025· 1 cited
A case of primary duodenal Brunner's gland hamartoma that gradually underwent morphological changes over a period of 10 years
DEN Open·2024· 1 citedOpen Access
The combined inhibition of SLC1A3 and glutaminase in osimertinib-resistant EGFR mutant cells
Biochimica et Biophysica Acta (BBA) - General Subjects·2024
Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology
International Journal of Clinical Oncology·2024
Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022
International Journal of Clinical Oncology·2024· 4 cited
Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology
Research Square (Research Square)·2024Open Access
Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology
International Journal of Clinical Oncology·2024
Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology
International Journal of Clinical Oncology·2024· 1 cited
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology
International Journal of Clinical Oncology·2024· 4 cited
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022
International Journal of Clinical Oncology·2024· 3 cited
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology
International Journal of Clinical Oncology·2024
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022
International Journal of Clinical Oncology·2024· 4 cited
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022
International Journal of Clinical Oncology·2024· 1 cited
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022
International Journal of Clinical Oncology·2024
page 1 of 16Next →

Frequent Co-authors

Katsuyuki Kiura(31), Nagio Takigawa(30), Katsuyuki Hotta(22), Eiki Ichihara(20), Mitsune Tanimoto(16), Hiromichi Yamane(14), Daijiro Harada(14), Toshio Kubo(11), Takashi Ninomiya(10), Yoshinobu Maeda(10), Masayuki Yasugi(9), Masahiro Tabata(9), Koji Inoue(9), Kadoaki Ohashi(8), Daisuke Minami(8), Yoshihiro Honda(8), Shinobu Hosokawa(7), Naohiro Oda(7), Kenichiro Kudo(7), Isao Oze(6)